New Antinuclear Antibody Testing: Does it Cut Costs and Corners Without Jeopardizing Clinical Reliability?

Daniel J Wallace


Nat Clin Pract Rheumatol. 2006;2(8):410-411. 

In This Article


Antinuclear antibodies (ANAs) are detected in the serum of patients with most systemic autoimmune diseases. The traditional tool used to detect ANAs is indirect immunofluorescence. A new, automated test, the ELiA Symphony, detects antibodies against a mixture of nuclear and cytoplasmic antigens (ENAs), in order to select sera samples that should be further tested using a more expensive, automated line immunoassay, the Lineblot test, to test for ANAs to non-antidouble-stranded-DNA.

The object of this study was to compare the cost and efficacy of indirect immunofluorescence for the detection of ANAs with a fully automated test, the ELiA Symphony, in order to diagnose autoimmune disease.

This study included sera samples from patients that were sent to the laboratory of Immunology at the University Hospital Utrecht to be tested for the presence of ANAs or anti-ENAs. Over a 4-month period, sera samples were evaluated using indirect immunofluorescence, the ELiA Symphony test and the Lineblot test. Sera testing positive for ANAs using indirect immunofluorescence were then tested for antidouble-stranded DNA antibodies, using the Farr assay. Results were compared to the incidence of signs and symptoms of systemic autoimmune disease, which was determined both before and after samples were taken.

The primary outcome measure of this trial was the comparative accuracy and cost-effectiveness of indirect immunofluorescence, the ELiA Symphony test and the Lineblot test in detecting ANAs related to systemic autoimmune disease.

In total, 328 sera samples were analyzed, of which 72 (22%) of samples were Lineblot positive. Of the 198 patients who did not have clinical indications of systemic autoimmune disease, 7% were Lineblot positive. When the Lineblot test was used to analyze only indirect-immunofluorescence-positive and ELiA-Symphony-positive samples, Lineblot-positive sera were not detected in either case (26 samples from the indirect-immunofluorescence group and 22 samples from the ELiA-Symphony group); a total of 15 samples were detected as negative for ANAs. This failure to detect reactivity was classified as clinically unimportant by the authors.

The authors conclude that patients who meet at least one criterion for systemic autoimmune disease can be restricted to the Lineblot test; this is both an efficacious and cost-effective strategy. Screening sera samples using indirect immunofluorescence or the ELiA Symphony test, when clinical symptoms of disease have not been observed, will strongly reduce the costs of anti-ENA detection. In this case, it is preferable to screen patients with indirect immunofluoresence, rather than the ELiA Symphony test.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.